

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
October 18, 2016**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES ACT OF 1933**

CRISPR Therapeutics AG

File No. 333-213577 - CF#34000

CRISPR Therapeutics AG submitted an application under Rule 406 requesting confidential treatment for information it excluded from the Exhibits to a Form S-1 registration statement filed on September 9, 2016, as amended.

Based on representations by CRISPR Therapeutics AG that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.1	through July 8, 2026
Exhibit 10.2	through July 8, 2026
Exhibit 10.3	through July 8, 2026
Exhibit 10.4	through July 8, 2026
Exhibit 10.5	through July 8, 2026
Exhibit 10.6	through July 8, 2026
Exhibit 10.7	through July 8, 2026

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields
Secretary